In Mark Foundation-Led Effort, More Than 100 Cancer Research Leaders Call for Biden Administration…

first_img Facebook WhatsApp Facebook By Digital AIM Web Support – February 9, 2021 TAGS  Twitter Twitter WhatsAppcenter_img Pinterest In Mark Foundation-Led Effort, More Than 100 Cancer Research Leaders Call for Biden Administration to Not Make Cancer Research a Casualty of COVID Local NewsBusiness Pinterest NEW YORK–(BUSINESS WIRE)–Feb 9, 2021– A group of more than 100 leaders from the nation’s top cancer research centers and philanthropic organizations sent an open letter to Xavier Becerra and Eric Lander, who have been nominated by President Biden to be Secretary of Health and Human Services and the Head of Office of Science and Technology Policy, respectively. “As the head of a foundation that funds promising pioneering cancer research, I have been seeing the devastating effects of COVID on cancer care and cancer research,” said Michele Cleary, PhD, CEO of the Mark Foundation for Cancer Research and the letter’s author. “We are calling on the new Administration to take action so that the substantial progress that has been achieved for patients does not revert and the breakthroughs that are poised to launch are not delayed.” The full letter with over 100 signatories, including senior leaders at prominent U.S. cancer research institutions and foundations,biotech leaders, and patient advocates is available on our website here. View source version on Shawn Jain, (415) 846-3707,[email protected] KEYWORD: UNITED STATES NORTH AMERICA DISTRICT OF COLUMBIA NEW YORK INDUSTRY KEYWORD: WHITE HOUSE/FEDERAL GOVERNMENT PUBLIC POLICY OTHER HEALTH OTHER POLICY ISSUES HEALTHCARE REFORM ONCOLOGY GENERAL HEALTH PHILANTHROPY INFECTIOUS DISEASES PUBLIC POLICY/GOVERNMENT CLINICAL TRIALS FOUNDATION SCIENCE OTHER SCIENCE RESEARCH HEALTH SOURCE: The Mark Foundation for Cancer Research Copyright Business Wire 2021. PUB: 02/09/2021 11:05 AM/DISC: 02/09/2021 11:05 AM Previous articleGlobal RG 7774 Pipeline Report 2021: Phase II (NCT04265261) of Clinical Trial for Diabetic Retinopathy – Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.comNext articleDustin Johnson withdraws from Pebble Beach Pro-Am Digital AIM Web Supportlast_img

Leave a Reply

Your email address will not be published. Required fields are marked *